Brice R. Suire
Oprichter bij Priothera Ltd.
Actieve functies van Brice R. Suire
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Financieel Directeur/CFO | 01-01-2020 | - |
Oprichter | 01-01-2020 | - | |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Financieel Directeur/CFO | 30-09-2020 | - |
Oprichter | 30-09-2020 | - |
Loopbaan van Brice R. Suire
Eerdere bekende functies van Brice R. Suire
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Novartis Biociências SA
Novartis Biociências SA Pharmaceuticals: GenericHealth Technology Novartis Biociências SA produces and markets generic drugs. Its solutions include generic and similar drugs, eye care products, and research. The company was founded on July 27, 1966 and is headquartered in Sao Paulo, Brazil. | Comptroller/Controller/Auditor | - | - |
Price Waterhouse y Audiberia SA
Price Waterhouse y Audiberia SA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Price Waterhouse y Audiberia SA is a Spanish company. | Corporate Officer/Principal | - | - |
Mazars SA
Mazars SA Miscellaneous Commercial ServicesCommercial Services Mazars SA provides auditing, financial, and legal services. It specializes in accounting, risk management, corporate strategy, litigation counseling, and taxation. It serves the finance, insurance, real estate, manufacturing, distribution, media, and healthcare sectors. The company was founded by Robert Mazars in 1940 and is headquartered in Courbevoie, France. | Corporate Officer/Principal | - | - |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Novartis Pharmaceuticals
Novartis Pharmaceuticals Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Pharmaceuticals is a German company that manufactures pharmaceutical products. The company is based in Basel, Germany. | Financieel Directeur/CFO | - | 10-01-2013 |
Corporate Officer/Principal | 10-01-2013 | - | |
MyoPowers Medical Technologies France SAS
MyoPowers Medical Technologies France SAS Medical SpecialtiesHealth Technology MyoPowers Medical Technologies France SA operates as a medical device company. It specializes in muscle technologies to restore or improve muscle function. The firm also develops implantable medical devices for the treatment of severe stress urinary incontinence. The company was founded by Piergiorgio Tozzi and Daniel Hyoz in June 2004 and is headquartered in Lausanne, Switzerland. | Financieel Directeur/CFO | - | - |
Opleiding van Brice R. Suire
Université Paris Dauphine-PSL | Undergraduate Degree |
Statistieken
Internationaal
Frankrijk | 5 |
Duitsland | 2 |
Verenigde Staten | 2 |
Operationeel
Director of Finance/CFO | 4 |
Corporate Officer/Principal | 4 |
Founder | 2 |
Sectoraal
Health Technology | 6 |
Commercial Services | 4 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 8 |
---|---|
MyoPowers Medical Technologies France SAS
MyoPowers Medical Technologies France SAS Medical SpecialtiesHealth Technology MyoPowers Medical Technologies France SA operates as a medical device company. It specializes in muscle technologies to restore or improve muscle function. The firm also develops implantable medical devices for the treatment of severe stress urinary incontinence. The company was founded by Piergiorgio Tozzi and Daniel Hyoz in June 2004 and is headquartered in Lausanne, Switzerland. | Health Technology |
Novartis Pharmaceuticals
Novartis Pharmaceuticals Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Pharmaceuticals is a German company that manufactures pharmaceutical products. The company is based in Basel, Germany. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Mazars SA
Mazars SA Miscellaneous Commercial ServicesCommercial Services Mazars SA provides auditing, financial, and legal services. It specializes in accounting, risk management, corporate strategy, litigation counseling, and taxation. It serves the finance, insurance, real estate, manufacturing, distribution, media, and healthcare sectors. The company was founded by Robert Mazars in 1940 and is headquartered in Courbevoie, France. | Commercial Services |
Price Waterhouse y Audiberia SA
Price Waterhouse y Audiberia SA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Price Waterhouse y Audiberia SA is a Spanish company. | Commercial Services |
Novartis Biociências SA
Novartis Biociências SA Pharmaceuticals: GenericHealth Technology Novartis Biociências SA produces and markets generic drugs. Its solutions include generic and similar drugs, eye care products, and research. The company was founded on July 27, 1966 and is headquartered in Sao Paulo, Brazil. | Health Technology |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Health Technology |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Health Technology |
- Beurs
- Insiders
- Brice R. Suire
- Ervaring